Skip to main content
. 2019 Jul 22;134(13):1024–1036. doi: 10.1182/blood.2018891598

Figure 1.

Figure 1.

Phase 1b schema and treatment duration. The phase 1b treatment schema is presented in panel A. Data on treatment duration are presented in panel B for patients in the all-treated population, with each bar representing an individual patient. Patients are ordered by the study initial dose date and color-coded by DLBCL subtype. The indicated lenalidomide dose was given in combination with 560 mg/day ibrutinib and 375 mg/m2 IV rituximab. PO, per os.